Supuran and colleagues found that selective CA9 inhibitors inhibited cell migration and spreading of breast cancer cells in the absence of oxygen, suggesting that CA9 is a pivotal target for antitumor therapy in patients with breast carcinoma [25,51]. This evidence concerns the gene CA9 and breast carcinoma.